Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure

Life Sciences

Volumn 85, Issue 11-12, 2009, Pages 431-437

  Gschwend, Simone ^a   Haug, Marcel Bernhard ^a   Nierhaus, Marc ^a   Schulz, Angela ^a   Vetter, Roland ^a   Kossmehl, Peter ^a   Orzechowski, Hans Dieter ^a   Scholze, Jürgen ^a   Rothermund, Lars ^b   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Charité Universitätsmedizin Berlin ^*  (Germany)

Author keywords

5 6 nephrectomy; Albuminuria; Beta blocker; EDHF; Endothelial dysfunction; Hypertension; Kidney; NO

Indexed keywords

ACETYLCHOLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; UREA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DISEASE MODEL; HYPERTENSION; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; MALE; NEPHRECTOMY; NONHUMAN; RAT; RENAL ARTERY; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ADRENERGIC BETA-ANTAGONISTS; ALBUMINURIA; ANIMALS; BENZOPYRANS; BIOLOGICAL FACTORS; CREATININE; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; KIDNEY; KIDNEY FAILURE, ACUTE; MALE; MICROCIRCULATION; NEPHRECTOMY; NITRIC OXIDE; NITROPRUSSIDE; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASODILATION; VASODILATOR AGENTS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 69549129282     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.07.006     Document Type: Article

References (45)

1. Altwegg L.A., d'Uscio L.V., Barandier C., Cosentino F., Yang Z., and Luscher T.F. Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries. Journal of Cardiovascular Pharmacology 36 (2000) 316-320
2. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F., Phillips R.A., Raskin P., Wright Jr. J.T., Waterhouse B., Lukas M.A., Anderson K.M., and Bell D.S. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46 (2005) 1309-1315
3. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., and Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94 (1996) 3341-3347
4. Benchetrit S., Green J., Katz D., Bernheim J., and Rathaus M. Early endothelial dysfunction following renal mass reduction in rats. European Journal of Clinical Investigation 33 (2003) 26-33
5. Bolotina V.M., Najibi S., Palacino J.J., Pagano P.J., and Cohen R.A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 368 (1994) 850-853
6. Bowman A.J., Chen C.P., and Ford G.A. Nitric oxide mediated venodilator effects of nebivolol. British Journal of Clinical Pharmacology 38 (1994) 199-204
7. Broeders M.A., Doevendans P.A., Bekkers B.C., Bronsaer R., van Gorsel E., Heemskerk J.W., Egbrink M.G., van Breda E., Reneman R.S., and van der Zee R. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 102 (2000) 677-684
8. Buikema H., Monnink S.H., Tio R.A., Crijns H.J., de Zeeuw D., and van Gilst W.H. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. British Journal of Pharmacology 130 (2000) 1999-2007
9. Cockcroft J.R., Chowienczyk P.J., Brett S.E., Chen C.P., Dupont A.G., Van N.L., Wooding S.J., and Ritter J.M. Nebivolol vasodilates human forearm vasculature. evidence for an L-arginine/NO-dependent mechanism. The Journal of Pharmacology and Experimental Therapeutics 274 (1995) 1067-1071
10. Cosentino F., Bonetti S., Rehorik R., Eto M., Werner-Felmayer G., Volpe M., and Luscher T.F. Nitric-oxide-mediated relaxations in salt-induced hypertension. effect of chronic beta1 -selective receptor blockade. Journal of Hypertension 20 (2002) 421-428
11. Dawes M., Brett S.E., Chowienczyk P.J., Mant T.G., and Ritter J.M. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. British Journal of Clinical Pharmacology 48 (1999) 460-463
12. Dessy C., Saliez J., Ghisdal P., Daneau G., Lobysheva I.I., Frerart F., Belge C., Jnaoui K., Noirhomme P., Feron O., and Balligand J.L. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 112 (2005) 1198-1205
13. Ding H., Kubes P., and Triggle C. Potassium- and acetylcholine-induced vasorelaxation in mice lacking endothelial nitric oxide synthase. British Journal of Pharmacology 129 (2000) 1194-1200
14. Doughty J.M., Plane F., and Langton P.D. Charybdotoxin and apamin block EDHF in rat mesenteric artery if selectively applied to the endothelium. The American Journal of Physiology 276 (1999) H1107-H1112
15. Gao Y.S., Nagao T., Bond R.A., Janssens W.J., and Vanhoutte P.M. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. Journal of Cardiovascular Pharmacology 17 (1991) 964-969
16. Georgescu A., Pluteanu F., Flonta M.L., Badila E., Dorobantu M., and Popov D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. European Journal of Pharmacology 508 (2005) 159-166
17. Georgescu A., Pluteanu F., Flonta M.L., Badila E., Dorobantu M., and Popov D. Nebivolol induces a hyperpolarizing effect on smooth muscle cells in the mouse renal artery by activation of beta-2-adrenoceptors. Pharmacology 81 (2008) 110-117
18. Griffin K.A., Picken M.M., Churchill M., Churchill P., and Bidani A.K. Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. Journal of the American Society of Nephrology : JASN 11 (2000) 497-506
19. Gschwend S., Buikema H., Navis G., Henning R.H., de Zeeuw D., and Van Dokkum R.P. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. Journal of the American Society of Nephrology : JASN 13 (2002) 2909-2915
20. Gschwend S., Pinto-Sietsma S.J., Buikema H., Pinto Y.M., van Gilst W.H., Schulz A., de Zeeuw D., and Kreutz R. Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney International 62 (2002) 181-191
21. Hart P.D., and Bakris G.L. Should beta-Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease?. Seminars in Nephrology 27 (2007) 555-564
22. Hasdan G., Benchetrit S., Rashid G., Green J., Bernheim J., and Rathaus M. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney International 61 (2002) 586-590
23. Ignarro L.J., Byrns R.E., Trinh K., Sisodia M., and Buga G.M. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 7 (2002) 75-82
24. Jiang F., and Dusting G.J. Endothelium-dependent vasorelaxation independent of nitric oxide and K(+) release in isolated renal arteries of rats. British Journal of Pharmacology 132 (2001) 1558-1564
25. Jolma P., Kalliovalkama J., Tolvanen J.P., Koobi P., Kahonen M., Saha H., and Porsti I. Preserved endothelium-dependent but impaired beta-adrenergic relaxation of the resistance vessels in experimental renal failure. Experimental Nephrology 10 (2002) 348-354
26. Kakoki M., Hirata Y., Hayakawa H., Nishimatsu H., Suzuki Y., Nagata D., Suzuki E., Kikuchi K., Nagano T., and Omata M. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 33 (1999) 467-471
27. Kalinowski L., Dobrucki L.W., Szczepanska-Konkel M., Jankowski M., Martyniec L., Angielski S., and Malinski T. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 107 (2003) 2747-2752
28. Kalliovalkama J., Jolma P., Tolvanen J.P., Kahonen M., Hutri-Kahonen N., Saha H., Tuorila S., Moilanen E., and Porsti I. Potassium channel-mediated vasorelaxation is impaired in experimental renal failure. The American Journal of Physiology 277 (1999) H1622-H1629
29. Kimura K., and Nishio I. Impaired endothelium-dependent relaxation in mesenteric arteries of reduced renal mass hypertensive rats. Scandinavian Journal of Clinical and Laboratory Investigation 59 (1999) 199-204
30. Kocks M.J., Gschwend S., de Zeeuw D., Navis G., and Buikema H. Low sodium modifies the vascular effects of angiotensin-converting enzyme inhibitor therapy in healthy rats. The Journal of Pharmacology and Experimental Therapeutics 310 (2004) 1183-1189
31. Kohler R., Eichler I., Schonfelder H., Grgic I., Heinau P., Si H., and Hoyer J. Impaired EDHF-mediated vasodilation and function of endothelial Ca-activated K channels in uremic rats. Kidney International 67 (2005) 2280-2287
32. Kreutz R., Kovacevic L., Schulz A., Rothermund L., Ketteler M., and Paul M. Effect of high NaCl diet on spontaneous hypertension in a genetic rat model with reduced nephron number. Journal of Hypertension 18 (2000) 777-782
33. Lamping K.G., Nuno D.W., Shesely E.G., Maeda N., and Faraci F.M. Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice. American Journal of Physiology. Heart and Circulatory Physiology 279 (2000) H1906-H1912
34. McEniery C.M., Schmitt M., Qasem A., Webb D.J., Avolio A.P., Wilkinson I.B., and Cockcroft J.R. Nebivolol increases arterial distensibility in vivo. Hypertension 44 (2004) 305-310
35. Nishikawa Y., Stepp D.W., and Chilian W.M. Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. American Journal of Physiology. Heart and Circulatory Physiology 279 (2000) H459-H465
36. Ochodnicky P., Vettoretti S., Henning R.H., Buikema H., Van Dokkum R.P., and de Zeeuw D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. Journal of Nephrology 19 (2006) 246-258
37. Pedersen M.E., and Cockcroft J.R. The vasodilatory beta-blockers. Current Hypertension Reports 9 (2007) 269-277
38. Pires M.J., Rodriguez-Pena A.B., Arevalo M., Cenador B., Evangelista S., Esteller A., Sanchez-Rodriguez A., Colaco A., and Lopez-Novoa J.M. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. Journal of Hypertension 25 (2007) 2486-2496
39. Ruilope L., Kjeldsen S.E., de La S.A., Mancia G., Ruggenenti P., Stergiou G.S., Bakris G.L., and Giles T.D. The kidney and cardiovascular risk--implications for management: a consensus statement from the european society of hypertension. Blood Pressure 16 (2007) 72-79
40. Schiffrin E.L., Lipman M.L., and Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 116 (2007) 85-97
41. Schulz A., Litfin A., Kossmehl P., and Kreutz R. Genetic dissection of increased urinary albumin excretion in the munich wistar fromter rat. Journal of the American Society of Nephrology : JASN 13 (2002) 2706-2714
42. Toprak O., Cirit M., Tanrisev M., Yazici C., Canoz O., Sipahioglu M., Uzum A., Ersoy R., and Sozmen E.Y. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Official Publication of the European Dialysis and Transplant Association - European Renal Association. Nephrology, Dialysis, Transplantation 23 (2008) 853-859
43. Van de Water A., Janssens W., Van Neuten J., Xhonneux R., De Cree J., Verhaegen H., Reneman R.S., and Janssen P.A. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. Journal of cardiovascular pharmacology 11 (1988) 552-563
44. Vettoretti S., Ochodnicky P., Buikema H., Henning R.H., Kluppel C.A., de Zeeuw D., and Van Dokkum R.P. Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats. Journal of Hypertension 24 (2006) 2215-2223
45. Waldron G.J., Ding H., Lovren F., Kubes P., and Triggle C.R. Acetylcholine-induced relaxation of peripheral arteries isolated from mice lacking endothelial nitric oxide synthase. British Journal of Pharmacology 128 (1999) 653-658